Bilthoven, The Netherlands, 23 February 2023 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced the appointment of Prof. dr. Virgil Schijns as Visiting Professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) of the University of Strathclyde in Glasgow, for a period of three years effective February, 2023.
The University of Strathclyde in Glasgow is recognized as a leading international technological university based in the centre of Glasgow. The appointment of Prof. Schijns will be in the context to further strengthen the pharmacy & biomedical sciences education and research capabilities, affirming its position as one of the foremost leading biomedical science schools in the world. With the overarching aim to build up specialist knowledge and deepen expertise within the field of immunological understanding and intervention of infectious diseases and cancer, during his three years assignment as Visiting Professor Schijns, will teach several courses. He will partake in research discussions and speak during lectures on the relevant areas, as well as participate in series of engagements with students, and academic colleagues.
Prof. Duncan Graham (Distinguished Professor, Associate Principal & Executive Dean of Science Faculty of Science) says:
“We’re delighted to appoint Prof. Schijns as a Visiting Professor to the University and to be based within our Institute for Pharmacy and Biomedical Sciences where his interactions and engagements will be hugely beneficial to all involved.”
Virgil Schijns studied Biomedicine at Utrecht University. He obtained his PhD in 1990 at the Utrecht University on “The Antiviral Activity of Interferon-gamma”. After working in Academia, at the Institute of Virology (Utrecht University), he joined the medical branch of AKZO-NOBEL (Intervet and Nobilon) as department head in 1997. Since 2013 he is the CSO at Epitopoietc Research Corporation (ERC), a clinical stage company which produces an immunotherapy for glioma brain cancer patients. In November 2020 he made the move to Intravacc, where he is the Chief Scientific Officer (CSO) and Chairman of the Scientific Advisory Board. Since 2000, Schijns has also been a frequent lecturer at North Carolina State University (USA) as Visiting Professor, and at Wageningen University as Special Professor, for various courses in the field of immunology and adjuvants. Virgil has published over 120 scientific articles in leading scientific journals.
“I’m honoured and grateful to be appointed as Visiting Professor at the University of Strathclyde and thrilled to have the chance to work with Strathclyde students and the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS).“